Showing 1001-1010 of 1364 results for "".
- Owing to the Advent of New Treatments, Melanoma Death Rates Drophttps://practicaldermatology.com/news/owing-to-the-advent-of-new-treatments-melanoma-death-rates-drop/2460312/Melanoma is killing the fewest Americans in decades, according to a study in the American Journal of Public Health. Death rates for metastatic melanoma among white Americans climbed 7.5 percent between 1986 and 2013, but then dropped by nearly 18 percent over the next thre
- Viper Equity Partners Seeks to Expand into Florida and Georgia Dermatology Marketshttps://practicaldermatology.com/news/viper-equity-partners-seeks-to-expand-into-florida-and-georgia-dermatology-markets/2460303/Viper Equity Partners is turning its attention to key dermatology and related aesthetics offices in Florida and Georgia to join private equity-backed partnerships. In an effort spearheaded by Senior Vice President Nina Das (see photo), the North Palm Beach-based M&A advisory firm is
- FDA Accepts NDA for Almirall's AK Drug Tirbanibulinhttps://practicaldermatology.com/news/fda-accepts-nda-for-almiralls-ak-drug-tirbanibulin/2460299/The FDA has reviewed and accepted the New Drug Application (NDA) from Almirall, SA for tirbanibulin, also known as ALM14789, for the treatment of actinic keratosis (AK). The FDA also communicated that it is not currently planning on holding an advisory committee to discuss the application. <
- Cold Plasma Patch May Make Immunotherapy More Effective for Treating Melanomahttps://practicaldermatology.com/news/cold-plasma-patch-may-make-immunotherapy-more-effective-for-treating-melanoma/2460275/A new medicated patch that can deliver immune checkpoint inhibitors and cold plasma directly to tumors may help boost the immune response and kill cancer cells, according to an interdisciplinary team of researchers at the UCLA Jonsson Comprehensive Cancer Center. The thumb-sized patch h
- South Beach Symposium Poised for 18th Miami Conferencehttps://practicaldermatology.com/news/south-beach-symposium-poised-for-18th-miami-conference/2460253/The 18th Annual South Beach Symposium takes place in Miami Beach next month. Organizers say the annual conference boasts an extensive agenda, with in-depth pre-conference offerings, and sessions topics covering the latest and most well-supported knowledge in clinical and aesthetic dermatology. Ro
- Researchers Elucidate Why Some Beta Blockers May Trigger or Exacerbate Psoriasishttps://practicaldermatology.com/news/researchers-elucidate-why-some-beta-blockers-may-trigger-or-exacerbate-psoriasis/2460211/Beta-blockers can trigger or exacerbate psoriasis, and now scientists at the University of Bonn and Freie Universität Berlin may know why. It appears that beta-blockers can interfere with the breakdown of defective cell components. In return, the cells release messengers that trigger immune-
- FDA Approves Amzeeq Minocycline Foam from Foamixhttps://practicaldermatology.com/news/fda-approves-amzeeq-minocycline-foam-from-foamix/2460194/The FDA has approved Amzeeq (minocycline) topical foam, 4%, from Foamix Pharmaceuticals for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. Amzeeq, formerly known as FMX101, is the first topical minoc
- Positive Top Line Results from Second Phase 3 Study of Abrocitinib for Atopic Dermatitishttps://practicaldermatology.com/news/positive-top-line-results-from-second-phase-3-study-of-abrocitinib-for-atopic-dermatitis-1/2460159/Pfizer Inc. shared positive top-line results from a second Phase 3 pivotal study evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis (AD). This is the second monotherap
- Pediatric Dermatologist Who Co-Founded Camp for Children Recognized for Carehttps://practicaldermatology.com/news/pediatric-dermatologist-who-co-founded-camp-for-children-recognized-for-care/2460153/The American Academy of Dermatology honored dermatologist Karen Wiss, MD, FAAD, as a Patient Care Hero for her role in treating a patient with recessive dystrophic epidermolysis bullosa (RDEB). To support pediatric patients with isolating conditions like RDEB, Dr. Wiss, a derm
- Melanoma Breakthrough: Researchers Discover Why Some Patients Respond to Immunotherapyhttps://practicaldermatology.com/news/melanoma-breakthrough-researchers-discover-why-some-patients-respond-to-immunotherapy-yet-others-dont/2460143/Israeli researchers now know why 60 percent of patients with metastatic melanoma do not respond to immunotherapy. After examining tumors of 116 patients using proteomics, the researchers found the non-responding patients tended to have lower fatty acid metabolism, meaning that their enz